Literature DB >> 28366605

Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.

Alan D T Barrett1.   

Abstract

Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Flavivirus; Fractional dosing; International health regulations; Vaccine; Yellow fever

Mesh:

Substances:

Year:  2017        PMID: 28366605     DOI: 10.1016/j.vaccine.2017.03.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

Review 1.  Zika, Chikungunya, and Other Emerging Vector-Borne Viral Diseases.

Authors:  Scott C Weaver; Caroline Charlier; Nikos Vasilakis; Marc Lecuit
Journal:  Annu Rev Med       Date:  2017-08-28       Impact factor: 13.739

2.  Motif V regulates energy transduction between the flavivirus NS3 ATPase and RNA-binding cleft.

Authors:  Kelly E Du Pont; Russell B Davidson; Martin McCullagh; Brian J Geiss
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

Review 3.  Zika virus research models.

Authors:  Jessica L Kublin; James B Whitney
Journal:  Virus Res       Date:  2017-08-12       Impact factor: 3.303

4.  A High-Throughput Yellow Fever Neutralization Assay.

Authors:  Madina Rasulova; Thomas Vercruysse; Jasmine Paulissen; Catherina Coun; Vanessa Suin; Leo Heyndrickx; Ji Ma; Katrien Geerts; Jolien Timmermans; Niraj Mishra; Li-Hsin Li; Dieudonné Buh Kum; Lotte Coelmont; Steven Van Gucht; Hadi Karimzadeh; Julia Thorn-Seshold; Simon Rothenfußer; Kevin K Ariën; Johan Neyts; Kai Dallmeier; Hendrik Jan Thibaut
Journal:  Microbiol Spectr       Date:  2022-06-07

5.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  CD-loop Extension in Zika Virus Envelope Protein Key for Stability and Pathogenesis.

Authors:  Emily N Gallichotte; Kenneth H Dinnon; Xin-Ni Lim; Thiam-Seng Ng; Elisa X Y Lim; Vineet D Menachery; Shee-Mei Lok; Ralph S Baric
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226

Review 7.  Conserved motifs in the flavivirus NS3 RNA helicase enzyme.

Authors:  Kelly E Du Pont; Martin McCullagh; Brian J Geiss
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-09-02       Impact factor: 9.957

8.  Wolbachia wStri Blocks Zika Virus Growth at Two Independent Stages of Viral Replication.

Authors:  M J Schultz; A L Tan; C N Gray; S Isern; S F Michael; H M Frydman; J H Connor
Journal:  mBio       Date:  2018-05-22       Impact factor: 7.786

Review 9.  Flavivirus NS1 and Its Potential in Vaccine Development.

Authors:  Kassandra L Carpio; Alan D T Barrett
Journal:  Vaccines (Basel)       Date:  2021-06-09

10.  Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D.

Authors:  Dan Li; Jing-Long Ye; Zhong-Yu Liu
Journal:  Virol Sin       Date:  2021-08-03       Impact factor: 6.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.